tert-butyl N-(2-phenylethoxysulfonyl)carbamate | 1375958-78-3

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl N-(2-phenylethoxysulfonyl)carbamate
• CAS: 1375958-78-3
• 化学式: C₁₃H₁₉NO₅S
• 分子量: 301.364
• InChiKey: HOSXKOZUJIQPHU-UHFFFAOYSA-N

物化性质

• 密度：
  1.232±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  90.1
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  tert-butyl N-(2-phenylethoxysulfonyl)carbamate 在 盐酸 作用下， 以 水 为溶剂， 以5.06 g的产率得到phenethyl sulfamate
  参考文献：
  名称：

  N-(tert-Butoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide: A Convenient Sulfamoylation Reagent for Alcohols

  摘要：

  A convenient and efficient procedure is described for the sulfamoylation of alcohols using N-(tertbutoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide (1). The ambient temperature stable reagent 1 reacts with phenols as well as primary and secondary alcohols to give high to modest yields. The relative reaction rate of substrates was determined (primary > phenol > secondary tertiary). The reagent's utility as a selective sulfamoylation reagent with polyols is also demonstrated.

  DOI：

  10.1021/ol3009683
• 作为产物：
  描述：

  苯乙醇 、 1-aza-4-azoniabicyclo[2.2.2]octan-4-ylsulfonyl(tert-butoxycarbonyl)azanido 1,4-diazabicyclo[2.2.2]octane monohydrochloride 以 乙腈 为溶剂， 反应 0.5h， 生成 tert-butyl N-(2-phenylethoxysulfonyl)carbamate
  参考文献：
  名称：

  N-(tert-Butoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide: A Convenient Sulfamoylation Reagent for Alcohols

  摘要：

  A convenient and efficient procedure is described for the sulfamoylation of alcohols using N-(tertbutoxycarbonyl)-N-[(triethylenediammonium)sulfonyl]azanide (1). The ambient temperature stable reagent 1 reacts with phenols as well as primary and secondary alcohols to give high to modest yields. The relative reaction rate of substrates was determined (primary > phenol > secondary tertiary). The reagent's utility as a selective sulfamoylation reagent with polyols is also demonstrated.

  DOI：

  10.1021/ol3009683

文献信息

• Preparation of Sulfamates and Sulfamides Using a Selective Sulfamoylation Agent
  作者：Hai-Ming Wang、Chao-Dong Xiong、Xiao-Qu Chen、Chun Hu、Dong-Yu Wang

  DOI：10.1021/acs.orglett.1c00504

  日期：2021.4.2

  Sulfamates and sulfamides are prevalent in biological molecules, but their universal synthetic methods are limited. We herein report a sulfamoylation agent with high solubility and shelf stability. Various sulfamates and sulfamides can be synthesized directly from alcohols or amines by employing this agent with high selectivity and high yields. This protocol was also successfully used for late-stage

  氨基磺酸盐和磺酰胺在生物分子中普遍存在，但它们的通用合成方法受到限制。我们在本文中报道了具有高溶解度和贮存稳定性的氨磺酰化剂。通过以高选择性和高收率使用该试剂，可以直接从醇或胺合成各种氨基磺酸盐和磺酰胺。该方案也已成功用于含有羟基或氨基基团的药物的后期氨磺酰化反应。
• Novel macrocyclic inhibitors of hepatitis C virus replication
  申请人：Blatt M. Lawrence

  公开号：US20070054842A1

  公开（公告）日：2007-03-08

  The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供一般式I至一般式VIII的化合物，以及包括药物组合物在内的组合物，其中包括一种主体化合物。本实施例还提供治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，这些方法通常涉及向需要治疗的个体施用一种主体化合物或组合物的有效量。
• NOVEL MACROCYCLIC INHIBITORS OF HEPATITIS C VIRUS REPLICATION
  申请人：Blatt Lawrence M.

  公开号：US20120208995A1

  公开（公告）日：2012-08-16

  The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供了一般式I至一般式VIII的化合物，以及包括药物组合物在内的组合物。实施例还提供了治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，通常涉及向需要的个体施用所述化合物或组合物的有效量。
• Novel Macrocyclic Inhibitors of Hepatitis C Virus Replication
  申请人：Blatt Lawrence M.

  公开号：US20090148407A1

  公开（公告）日：2009-06-11

  The embodiments provide compounds of the general Formulae (I) through general Formula (VIII), as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本实施例提供通式（I）到通式（VIII）的化合物，以及包括制药组合物在内的组合物，其中包括主体化合物。本实施例还提供治疗方法，包括治疗丙型肝炎病毒感染和治疗肝纤维化的方法，通常涉及向需要治疗的个体施用所述主体化合物或组合物的有效量。
• Macrocyclic inhibitors of Hepatitis C virus replication
  申请人：Intermune, Inc.

  公开号：EP2305695A2

  公开（公告）日：2011-04-06

  The embodiments provide compounds of the general Formulae I through general Formula VIII, as well as compositions, including pharmaceutical compositions, comprising a subject compound. The embodiments further provide treatment methods, including methods of treating a hepatitis C virus infection and methods of treating liver fibrosis, the methods generally involving administering to an individual in need thereof an effective amount of a subject compound or composition.

  本发明的实施方案提供了通式I至通式VIII的化合物，以及包含主题化合物的组合物，包括药物组合物。本发明的实施方案进一步提供了治疗方法，包括治疗丙型肝炎病毒感染的方法和治疗肝纤维化的方法，这些方法一般涉及向有需要的个体施用有效量的主体化合物或组合物。